Loading
A phase 2 trial of sacituzumab tirumotecan and anlotinib in lung cancer, run by Sichuan University, not yet recruiting.
Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) is a phase 2, interventional study registered as NCT07501169 by Sichuan University, with a registry enrolment figure of 33 participants, started 2026-04-01 and due to reach its primary completion in 2027-08-31. Interventions recorded: Sacituzumab Tirumotecan and Anlotinib. Conditions listed: Extensive-stage Small Cell Lung Cancer (ES-SCLC). Primary outcome: Objective Response Rate (ORR). Lung eligibility wording from the registry: "Histologically or cytologically confirmed small cell lung cancer (SCLC) based on pathology and immunohistochemistry/immunophenotyping results; disease staged as extensive-stage SCLC (ES-SCLC) according to the Veterans Administration Lung Study Group (VALG) staging system". Sites: China. No results are recorded here; the registry entry is the source.
Shares Anlotinib, Extensive-stage small-cell lung cancer, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Extensive-stage small-cell lung cancer, Anti-angiogenic therapy and the tag lung-deep-dive.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Sacituzumab tirumotecan, Lung cancer trials open today (registry snapshot), Antibody-drug conjugate (ADC) and the tag lung-deep-dive.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Lung cancer trials open today (registry snapshot), Antibody-drug conjugate (ADC) and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.